GenScript ProBio will promote and advertise Calidi Biotherapeutics’ allogeneic cell technology platform SNV-1 to current and future clients.

Millie Nelson, Editor

June 14, 2021

2 Min Read
GenScript to distribute Calidi’s ‘trojan horse’ cell therapy tech
Image: iStock/scyther5

GenScript ProBio will promote and advertise Calidi Biotherapeutics’ allogeneic cell technology platform SNV-1 to current and future clients.

Under the terms of the agreement, Calidi will train and equip the Genscript sales team to present its SuperNova-1 (SNV-1) technology to their current customers.

According to the firm, it recognizes the problems that surround oncolytic viruses as the immune system of the patient attacks and eliminates a large amount of the oncolytic virus from the body.

iStock-1208673733-300x127.jpg

Image: iStock/scyther5

“In many cases, 95%+ of the oncolytic virus is removed from the body within five minutes of receiving the treatment,” COO of Calidi Biotherapeutics Stephen Thesing told BioProcess Insider.

SNV-1 “utilizes stem cells which act as a trojan horse to both protect and potentiate (amplify) the oncolytic virus from the immune system of the patient,” said Thesing. “This ensures a robust and effective army of oncolytic virus to attack and kill the cancer.”

Contract research organization (CRO) and contract development manufacturing organization (CDMO) GenScript ProBio has a global sales team consisting of more than 300 people who will be trained and equipped with resources to promote and advertise the SNV-1 technology.

GenScript will also negotiate possible manufacturing and licensing agreements with interested clients.

Additional advertising and promotion programs are being developed by Caldi for future deployment.

A figure has not been disclosed but Thesing told us that “GenScript ProBio will pay Calidi a low double-digit percentage of the net revenue produced by its SNV-1 manufacturing services per the agreement reached.”

“This means that Genscript will utilize their GMP facilities to manufacture and deliver the Calidi SNV-1 solution to clients that are secured by Genscript on behalf of Calidi.”

The initial term of this agreement is five years.

About the Author(s)

Millie Nelson

Editor, BioProcess Insider

Journalist covering global biopharmaceutical manufacturing and processing news and host of the Voices of Biotech podcast.

I am currently living and working in London but I grew up in Lincolnshire (UK) and studied in Newcastle (UK).

Got a story? Feel free to email me at [email protected]

You May Also Like